Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• histologically confirmed thymic carcinoma

• surgically inoperable Masaoka stage III or IV

• ECOG 0-2

• at least one measurable disease

Exclusion Criteria:

• previous myocardiac infarct history within 1 year before the enrollment.